ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Lipid Nanoparticle-encapsulated EBV mRNA Vaccine mRNA-1189

Its studies are mostly in Epstein-Barr Virus Infections, led by Moderna.

Furthest: phase 2, since Dec 1, 20212 company-led studies, 2 open or runningNext primary completion: May 15, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Moderna22 open or runningphase 2since Dec 1, 2021Dec 1, 2021May 15, 2027phase 1 · NCT07478952

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 1, 2021First study: phase 2 study in Epstein-Barr Virus InfectionsFirst studyNCT05164094 · 867 enrolled · United States
  2. Mar 13, 2026Phase 1 study in Epstein-Barr Virus InfectionsNCT07478952 · 120 planned · Australia

Ahead

  1. May 15, 2027Primary completion: phase 1 study in Epstein-Barr Virus InfectionsNCT07478952

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“A vaccine consisting of a lipid nanoparticle (LNP) encapsulating four messenger RNAs (mRNAs) encoding the Epstein-Barr Virus (EBV) envelope glycoproteins gp42, gp220, gH and gL, ”NCIt, by rule
“Lipid Nanoparticle-encapsulated EBV mRNA Vaccine mRNA-1189”name, by rule

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07478952Epstein-Barr Virus Infections · Australia1RecruitingMay 15, 2027120
NCT05164094Epstein-Barr Virus Infections · United States2Active, not recruitingOct 5, 2026867

How it is read

Names in the registry

  • “mRNA-1189”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.